Overview

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

A Phase II study that evaluating the efficacy and safety of pembrolizumab in combination with chemotherapy as neoadjuvant therapy for triple-negative breast cancer in the Chinese population

Phase:

Phase 2

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Treatments:

Cyclophosphamide
Epirubicin
Paclitaxel
Pembrolizumab